NMN and Wound Healing: NAD+ for Dermal Regeneration

NMN wound healing is an emerging area of interest for researchers studying how NAD+ metabolism influences tissue repair. While most public attention has focused on NMN's role in energy metabolism and aging, the underlying biology of NAD+ has direct implications for skin regeneration and dermal recovery. This article examines what the current evidence actually says about nicotinamide mononucleotide and wound repair, drawing only from published human trials and preclinical studies.

NMN Wound Healing: What the Research Landscape Actually Shows

The connection between NMN and wound healing is primarily inferred from NAD+ biology rather than direct human clinical trials. To date, no published human randomized controlled trial has specifically tested NMN for wound healing outcomes. The evidence base consists of mechanistic studies, animal models, and human trials that measure NAD+ elevation as a primary endpoint with potential downstream implications for tissue repair.

In a 12-week randomized trial, Yoshino et al. (2021) demonstrated that NMN 250 mg/day increased muscle insulin sensitivity in prediabetic women (n=25). While wound healing was not measured, improved insulin signaling is relevant because hyperglycemia impairs dermal fibroblast function and collagen deposition in diabetic wounds. Igarashi et al. (2022) showed that NMN 300 mg/day for 12 weeks elevated blood NAD+ levels in healthy subjects with mild sleep disturbance (n=108). Elevated NAD+ pools could theoretically support the PARP-mediated DNA repair processes that are active during tissue regeneration.

Fukamizu et al. (2022) administered NMN 125–500 mg/day to healthy Japanese men (n=11) and confirmed dose-dependent increases in plasma NMN and NAD+ metabolites. The small sample size limits generalizability, but the pharmacokinetic data help contextualize whether oral NMN reaches concentrations relevant to dermal tissue. Mills et al. (2016) conducted long-term NMN administration in aged mice and observed improved vascular function, eye function, and physical activity—outcomes that suggest systemic tissue maintenance benefits, though murine data do not translate directly to human wound healing.

Garten et al. (2015) established the foundational role of NAD+ biosynthesis through NAMPT in cellular stress responses, including inflammation and DNA repair. This review-level evidence frames why researchers are interested in NMN wound healing, but it does not constitute clinical proof of efficacy for skin repair.

How NAD+ Supports NMN Wound Healing at the Cellular Level

NMN wound healing biology centers on NAD+ as a cofactor for enzymes critical to tissue repair. When skin is injured, the repair cascade involves inflammation, proliferation, and remodeling phases. Each phase has specific NAD+ dependencies that explain the mechanistic rationale for NMN supplementation.

PARP Enzymes and DNA Repair in Damaged Tissue

Poly(ADP-ribose) polymerases (PARPs) consume NAD+ to detect DNA strand breaks and recruit repair machinery. In wounded tissue, replicating keratinocytes and fibroblasts experience oxidative stress that damages DNA. Without adequate NAD+, PARP activity becomes substrate-limited and cells may undergo apoptosis instead of productive repair. Igarashi et al. (2022) demonstrated that oral NMN can raise human NAD+ levels, which in principle removes this bottleneck, though no study has measured PARP activity in human skin after NMN administration.

Sirtuins and Tissue Remodeling

Sirtuin 1 (SIRT1), an NAD+-dependent deacetylase, regulates inflammation and extracellular matrix remodeling. In preclinical models, SIRT1 activation reduces pro-inflammatory cytokine production during the early inflammatory phase of wound healing, potentially preventing chronic wounds. Garten et al. (2015) reviewed how NAD+ availability directly controls sirtuin activity across tissues. The relevance to human dermal regeneration remains theoretical because tissue-specific sirtuin activation by oral NMN has not been demonstrated in clinical trials.

Mitochondrial Energy for Proliferating Cells

Wound healing requires rapid cell division. Fibroblasts migrating into a wound bed depend on ATP synthesis for motility and collagen synthesis. NAD+ is an electron carrier in oxidative phosphorylation. Mills et al. (2016) showed that long-term NMN administration in mice preserved mitochondrial function in multiple tissues. Whether this translates to faster re-epithelialization or stronger tensile strength in human wounds is unknown.

NMN Wound Healing Dosage and Form Comparison

Because no human trial has tested NMN specifically for wound healing, any dosage recommendation is extrapolated from studies with other primary endpoints. The table below summarizes the human NMN trials relevant to inferring a dose range for tissue repair contexts.

<

Study	Population	Dose	Duration	NAD+ Elevation	Wound-Relevant Endpoint
Yoshino 2021	Prediabetic women (n=25)	250 mg/day	10 weeks	Yes (muscle NAD+)	Insulin sensitivity (indirect)
Igarashi 2022	Healthy adults with sleep disturbance (n=108)	300 mg/day	12 weeks	Yes (blood NAD+)	Sleep quality, fatigue (indirect)
Fukamizu 2022	Healthy Japanese men (n=11)	125–500 mg/day	12 weeks	Yes (dose-dependent plasma)	Clinical safety, metabolites

Key observations from the available data: doses between 250 mg and 500 mg per day have been tolerated without serious adverse events in short-to-medium term trials. NAD+ elevation appears dose-dependent up to at least 500 mg/day. No study has exceeded 12 weeks of continuous administration, so long-term safety for wound healing contexts is not established. For readers interested in how NAD+ supports broader skin maintenance, see our article on NMN for Skin Health: How NAD+ May Support Collagen Synthesis and Reduce Aging.

PEPAX NMN provides 500 mg per capsule, which aligns with the upper end of the studied human dose range. Individuals considering NMN for recovery support should recognize that this dose is extrapolated from general NAD+ trials, not from wound healing-specific research.

Who Benefits Most from NMN Wound Healing Support

Because direct clinical evidence is absent, the most defensible approach is to identify populations where NAD+ biology is most likely to be relevant to tissue repair, based on comorbidities and physiological states.

Older Adults with Slow Healing

NAD+ levels decline with age in multiple tissues. Mills et al. (2016) showed that restoring NAD+ in aged mice improved markers of tissue maintenance. Older adults experience delayed wound healing partly due to reduced fibroblast proliferation and collagen synthesis. Whether NMN supplementation reverses this in humans is speculative but mechanistically plausible.

Individuals with Metabolic Dysfunction

Yoshino et al. (2021) demonstrated that NMN improved insulin sensitivity in prediabetic women. Impaired glucose metabolism is a well-established risk factor for poor wound healing, particularly in diabetic foot ulcers. NMN may support wound healing indirectly by improving metabolic control, though this has not been tested in a wound healing trial.

Those Recovering from Surgery or Injury

The acute phase of tissue repair after surgery involves high NAD+ demand for PARP activation, inflammation resolution, and cell proliferation. Individuals with low baseline NAD+ status—due to age, chronic stress, or poor sleep—may be the most likely to benefit from supplementation. Igarashi et al. (2022) found that NMN improved fatigue and sleep quality in subjects with mild sleep disturbance, suggesting that populations with suboptimal recovery may experience broader benefits that could extend to tissue repair.

For readers exploring antioxidant strategies alongside NAD+ support, our article on Hydrogen Water and Wound Healing: The Oxidative-Stress Angle on Skin Repair examines molecular hydrogen as a complementary approach targeting reactive oxygen species in damaged tissue.

NMN Wound Healing: Practical Takeaways

• No human clinical trial has directly tested NMN for wound healing speed or scar quality. All claims about NMN wound healing are mechanistically inferred from NAD+ biology.
• Human studies using 250–500 mg/day NMN have demonstrated NAD+ elevation without serious adverse events over 10–12 weeks. This is the evidence-based dose range for general NAD+ support.
• NAD+ is required for PARP-mediated DNA repair, sirtuin-regulated inflammation control, and mitochondrial ATP production—all processes active during tissue repair.
• Older adults, individuals with insulin resistance, and those with poor sleep or high fatigue may be the populations most likely to benefit from NAD+ repletion, though wound-specific outcomes remain unstudied.
• NMN should not replace standard wound care. It is not a treatment for infected wounds, diabetic ulcers, or surgical incisions. Consult a healthcare provider for any non-healing wound.
• For those interested in the DNA repair mechanisms underlying NAD+ biology, see NMN and DNA Repair: How NAD+ Fuels PARP Enzymes to Fix Damaged Strands.

The Bottom Line on NMN Wound Healing

The biological rationale for NMN wound healing is sound: NAD+ is a required cofactor for enzymes that repair DNA, regulate inflammation, and power the proliferating cells that close wounds. However, the evidence gap is substantial. No human trial has measured wound closure, tensile strength, or scar outcomes after NMN supplementation. The available human data show that oral NMN raises NAD+ levels safely at doses of 250–500 mg per day, which supports further research but does not justify clinical claims about wound healing efficacy. For now, NMN is best viewed as a general NAD+ support strategy with theoretical relevance to tissue repair, not a proven wound healing intervention.

---

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels in healthy subjects with mild sleep disturbance." NPJ Aging. 2022;8(1):5. [Source]
3. Fukamizu Y, et al. "Effects of orally administered nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Scientific Reports. 2022;12:6134. [Source]
4. Mills KF, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metabolism. 2016;24(6):795–806. [Source]
5. Garten A, et al. "Physiological and pathophysiological roles of NAMPT and NAD metabolism." Nature Reviews Endocrinology. 2015;11(9):535–546. [Source]

---

---